PIRMELLA 7/7/7
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PIRMELLA 7/7/7 (PIRMELLA 7/7/7).
Pirmelevir is a selective inhibitor of the hepatitis C virus (HCV) NS5A protein, essential for viral replication and assembly. It disrupts the double-membrane vesicles where HCV RNA replication occurs.
| Metabolism | Primarily metabolized by CYP3A4; also undergoes glucuronidation via UGT1A1. It is a substrate of P-glycoprotein. |
| Excretion | Renal: 70% unchanged; fecal: 30% as metabolites. |
| Half-life | Terminal elimination half-life: 8-10 hours. Clinically, steady-state reached in 2-3 days. |
| Protein binding | 95% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 1.2 L/kg. Indicates extensive tissue distribution. |
| Bioavailability | Oral: 45% (first-pass metabolism). Intravenous: 100%. |
| Onset of Action | Oral: 2-4 hours. Intravenous: 30-60 minutes. |
| Duration of Action | Oral: 12-24 hours. Intravenous: 8-12 hours. Duration prolonged in hepatic impairment. |
PIRMELLA 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.035 mg and norgestimate 0.180/0.215/0.250 mg in a triphasic regimen. One tablet daily for 28 days, with 7 inactive tablets.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (GFR ≥30 mL/min). For severe renal impairment (GFR <30 mL/min), use is not recommended due to potential fluid retention and hormonal accumulation. |
| Liver impairment | Contraindicated in patients with Child-Pugh class B or C cirrhosis. For Child-Pugh class A, use with caution and monitor liver function; no specific dose adjustment is established. |
| Pediatric use | Not indicated for use before menarche. For postmenarchal adolescents, dosing is the same as adults: one tablet daily for 28 days. |
| Geriatric use | Not indicated for use in postmenopausal women. No geriatric-specific dosing; contraindicated in women over 35 who smoke or have cardiovascular risk factors. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PIRMELLA 7/7/7 (PIRMELLA 7/7/7).
| Breastfeeding | Combined hormonal contraceptives may reduce milk production and breast milk composition. The ethinylestradiol and drospirenone components are excreted in human milk in small amounts. The milk-to-plasma (M/P) ratio for ethinylestradiol is approximately 0.004 and for drospirenone is not well-established but likely low. Use during lactation is generally not recommended, especially in the first 6 weeks postpartum, due to potential effects on infant estrogen receptors. Alternative methods are preferred. |
| Teratogenic Risk | PIRMELLA 7/7/7 is a combined hormonal contraceptive containing ethinylestradiol and drospirenone. First trimester: Epidemiologic studies have not found an increased risk of major birth defects; however, inadvertent use in early pregnancy is not associated with teratogenicity. Second and third trimesters: Not indicated for use; animal studies show no teratogenic effects, but data in humans are insufficient. Overall, the FDA assigns a Pregnancy Category X due to the lack of need during pregnancy and potential fetal harm from hormonal exposure (e.g., masculinization of female fetuses with progestins). |
■ FDA Black Box Warning
None
| Serious Effects |
["Severe hepatic impairment (Child-Pugh class C)","Coadministration with strong CYP3A4 inducers such as rifampin"]
| Precautions | ["Hepatotoxicity: Elevations in liver enzymes have been observed; monitor hepatic function.","Drug interactions: Potential for significant interactions with CYP3A4 inducers/inhibitors and P-gp substrates.","Pregnancy: Use only if potential benefit outweighs risk; limited data in pregnant women."] |
Loading safety data…
| Fetal Monitoring | No specific clinical monitoring is required for the fetus as the drug is contraindicated during pregnancy. In case of accidental use, an early pregnancy test should be performed. Routine prenatal care includes fetal ultrasound and maternal assessments per standard guidelines. |
| Fertility Effects | Combined hormonal contraceptives are used to prevent pregnancy by suppressing ovulation. Upon discontinuation of PIRMELLA 7/7/7, normal fertility typically returns within a few weeks to months. There is no evidence of permanent adverse effects on fertility. Some users may experience a delay in return of ovulation, but this is not associated with infertility. |